NorthView Acquisition Corp.

General Information

It is our intention to pursue prospective targets that are focused on healthcare innovation. We anticipate targeting what are traditionally known as “small cap” companies domiciled in North America, Europe and/or the Asia Pacific (“APAC”) regions that are developing assets in the biopharmaceutical, medical technology/medical device and diagnostics space which aligns with our management team’s experience in operating health care companies and in drug and device technology development as well as diagnostic and other services. We will search for target companies with enterprise values ranging from $500 million to $2 billion.

(Note: NorthView Acquisition Corp. upsized its SPAC IPO at pricing on Dec. 20, 2021, to 16.5 million units, up from 15 million, at $10 each to raise $165 million. NASDAQ said the IPO would be released on Nasdaq today (Monday, Dec. 20, 2021) for quotation at 2:20 p.m. EST and the stock would be eligible for trading at about 2:30 p.m. EST.)



Employees: 0
Founded: 2021
Contact Information
Address 207 West 25th St, 9th Floor New York, NY 10001
Phone Number (212) 494-9022
Web Address
View Prospectus: NorthView Acquisition Corp.
Financial Information
Market Cap $200.0mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol NVACU
Exchange NASDAQ
Shares (millions): 16.5
Price range $10.00 - $10.00
Est. $ Volume $165.0 mil
Manager / Joint Managers I-Bankers Securities / Dawson James Securities
CO-Managers -
Expected To Trade: 12/20/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change